Research on Personalized Medicine (PerMed) is a top priority for the European Union (EU) as a strategy aimed at delivering personalised health and care solutions to benefit citizens. In order to strengthen the global efforts on Personalized Medicine and the cooperation of Europe (EU) with Latin American and Caribbean (LAC)  countries , the EULAC PerMed project, funded by the Horizon 2020 Programme of the European Commission, has been launched in January 2019. A unique bi-regional consortium of governmental and funding organisations, with the support of leading stakeholders as associated partners, will be in charge of developing the project until December 2021.

As already stated by the European Council (2015/C 421/03), there is no commonly agreed definition of the term ‘personalised medicine’. However, it is widely understood that personalised medicine refers to a medical model using characterisation of individuals’ phenotypes and genotypes (e.g. molecular profiling, medical imaging, lifestyle data) for tailoring the right therapeutic strategy for the right person at the right time, and/or to determine the predisposition to disease and/or to deliver timely and targeted prevention. Personalised medicine relates to the broader concept of patient-centred care, which takes into account that, in general, healthcare systems need to better respond to patient needs. A frequently synonym used for ‘personalised medicine, is ‘precision medicine’, but sometimes other terms as ‘individualised medicine’, ‘personalised precision medicine’, etc., are also used.

EULAC PerMed has the ambition to engage LAC countries in the International Consortium on Personalized Medicine (ICPerMed) and in the ERANet ERAPerMed with the aim at advancing in the implementation of the Action Plan of ICPerMed. EULAC PerMed will be the vehicle for:

  1. Mapping existing programmes, capacities and expertise and gaps in CELAC countries.
  2. Facilitating the incorporation of LAC countries in ICPerMed and in the ERAPerMed.
  3. Fostering the participation of LAC countries in research mobility and transnational projects on PerMed, and a platform for EU‐LAC collaboration on clinical trials PerMed focused.
  4. Cross-border learning from Research and Innovation  and the ethical, legal and social aspects for implementing innovations between research capacities based in EU and LAC.
EULAC PerMed has been funded by the European Union’s Horizon 2020 Research and Innovation programme under Grant Agreement Num. 825173.